



Next version of scanner installed and tested by Krzysztof Krawczyk, Project Manager (left). Alexander Carr, life science consultant at TTP plc delivered and supported the installation, here with Lumito's CTO Andreas Johansson (right).

## Scanner with improved functionality installed

A life science consultant from TTP plc has delivered the next version of the Lumito's scanner, with improved functionality, and assisted in the installation process. The new scanner entails, among other things, greater capacity to test new indications and to complete the evaluation of the breast cancer marker Her2.

- Due to the pandemic, this was the first time in a year that we had the opportunity to meet physically, which was most welcome. Both the installation and tests went according to plan and we also had the opportunity to discuss and plan the next development steps together, says Andreas Johansson, CTO at Lumito.

### For further information, please contact

Mattias Lundin, CEO of Lumito, e-mail: [ml@lumito.se](mailto:ml@lumito.se), ph. +46 768 68 45 09.  
Please also visit our website.

**Lumito** specializes in imaging technology within medical research and development. The technology is based on so called UCNPs (Up Converting Nano Particles) and is aiming to increase image quality in biomedical applications. Lumito's IPR covers high-quality imaging of tissue, for instance in tumours, with UCNPs as markers. The technology has several possible application areas, but Lumito has initially decided to focus on digital pathology.

Lumito's share is traded under the ticker LUMITO on the Nordic Growth Market, NGM SME, where the Company's mentor is G&W Fondkommission, telephone: +468-503 000 50.